United States Patent 10,017,492: What the Isoindoline Claims Actually Cover and Where the Landscape Breaks
What does US 10,017,492 claim in scope?
US 10,017,492 is drafted as a broad “generic-structure” patent centered on an isoindoline derivative defined by a general formula (I), with coverage extended across salt forms, polymorphs, stereoisomers, isotopic compounds (deuterated variants), and metabolites.
The claims are not limited to a single molecule; Claim 1 builds a large combinatorial chemical space by varying:
- Core ring substituent framework via parameters including n1 (0 or 1) and Z (substituent defined in the claim)
- Deuterium and isotopic substitution across many positions (R1, R3, R4, R5, R6, R7, R8, R9 are independently H or D; additional D options appear for R10 and R2)
- Halogen vs H/D choices (notably R2 ∈ {H, D, halogen})
- Alkyl and heterocycloalkyl substituent sets including:
- L1, L2 ∈ {CD2, CHD, CH2}
- X ∈ {NH, ND, O}
- R10 is defined as either H/D or a specific substituent (formula shown in claim), which then drives further substitution at R2’, R3’, R4’, R5’
- “Substituted or unsubstituted” size ranges across (C1-C12)alkyl and (C2-C20)heterocycloalkyl, plus specific sub-preferences in dependent claims
The patent also covers process claims (Claims 9–17) for making the formula (I) compounds via sequential deprotection/amidation, reductions, reductive amination, coupling, and deprotection routes using named intermediate “A-05/A-06/P-01/I-RS” series.
How broad is Claim 1, practically?
Claim 1 includes several scope-broadening devices that materially expand coverage beyond a typical single-compound claim set:
-
Multiple “legal forms” of the same structure are claimed simultaneously
- pharmaceutically acceptable salts
- polymorphs
- stereoisomers
- isotopic compounds
- metabolites
-
Deuteration is baked into the independent claim
- Multiple substituents are defined as independently H or D, and R2 includes D, while L1/L2 include deuterated methylene variants (CD2/CHD/CH2).
- This structure language typically captures both specific deuterated embodiments and a family that can be tuned positionally.
-
Dependent-claim narrowing still leaves a large “within-the-box” space
- Dependent claims constrain preferred heterocycles, alkyl size, and specific substitution motifs around the R10 substituent, but they repeatedly use ranges like C1–C4 and heterocycles with 1 or 2 heteroatoms (N or O). That is still chemically broad.
-
Claim 8 is an enumerated “examples list,” but the independent claim already covers them
- Claim 8 lists a large set of formula (I) embodiments (many structures presented as “##STR00468## … ##STR00634##” placeholders in the excerpt you provided).
- This enumeration often helps enforceability (written description support and enablement for examples) while independent claim language remains the main infringement hook.
What do Claims 2–8 add (and what they do not)?
Claim 2: stereochemical and Z-variant coverage
Claim 2 specifies:
- the asymmetric center refers to achiral carbon, (S)/(R) and enriched (S)/(R), or racemate
- Z is selected from specific alternatives (listed via claim drawings)
This does two things:
- It explicitly prevents an argument that the stereochemical definition is ambiguous.
- It expands “Z” coverage to enumerated substituent patterns, not a continuous range.
Claim 3–4: preferential heterocycle and tighter substituent definition under R10
Claim 3 adds preferences that narrow heterocycle identity and specific alkoxy and acyl variants:
- heterocycloalkyl is preferably (C2–C6) heterocycloalkyl with 1 or 2 heteroatoms selected from N or O
- when R10 is a specific substituent, R2’–R5’ are constrained to specific groups such as substituted alkoxy (and in later dependencies, substituted to specific (C1–C4) alkoxy)
- it defines structures for parts of the claim via drawings: substituted alkoxy substituent patterns and specific alkylacyl motifs
Claim 4 then further narrows:
- the (C2–C6) heterocycle is pyrrolidine, morpholinyl, or piperazinyl
- deuterated heterocycloalkyl substituents are tied to specific drawn moieties
- alkyl sizes are constrained: in multiple places (C1–C4) alkyl, including methyl/ethyl/n-propyl/iso-propyl/n-butyl/iso-butyl/tert-butyl
- alkoxy is constrained to (C1–C4) alkoxy, including methoxy/ethoxy/propoxy/butoxy isomers
Claim 5–6: “R10 is a halogenated or alkyl/alkoxy substituted motif”
Claim 5 limits R2’–R5’ depending on the identity of R10:
- if R10 is a drawn substituent, then R2’–R5’ are halogens (F, Cl, Br, I)
- if R10 is another drawn motif, then R2’–R5’ are (C1–C12) alkyl, narrowed further to (C1–C4) in later clause
- for certain R10 motifs, R2’–R5’ are substituted or unsubstituted (C1–C12)alkoxy, narrowed to (C1–C4)alkoxy
Claim 6 tightens further:
- alkyl is limited to small (C1–C4) alkyl and branched/isomeric variants
- alkoxy similarly limited to methoxy/ethoxy/n-propoxy/isopropoxy/n-butoxy/isobutoxy/tert-butoxy
- it also constrains R2’–R5’ drawn groups to a smaller “alkoxy structure set”
Claim 7
Claim 7 is an R10-specific definition using multiple drawn substituent patterns. In practice, it provides additional discrete sub-embodiments under the Claim 1 scaffolding.
Claim 8
Claim 8 enumerates a broad set of specific formula (I) compounds, which can support:
- written description breadth
- enablement of many embodiments
- identification of near-design-around alternatives (if competitors are practicing variants close to listed examples)
What Claims 2–8 do not do
They do not define:
- a specific target receptor/biological pathway (they are TNF-alpha treatment claims in method claims)
- a specific dose, regimen, or patient subgroup as an essential limitation
- manufacturing constraints (process claims exist, but composition/method-of-use claims are not tied to process parameters)
That matters because it keeps infringement potential broad at the composition and method levels.
Where the patent landscape tends to concentrate (and why this matters here)
Without additional bibliographic details such as application numbers, priority dates, assignees, or cited art, the landscape analysis must focus on structural claim patterns and claim-level mechanisms. Those patterns typically correlate with three landscape battlegrounds in isoindoline TNF-alpha programs:
1) “Deuterated analog” families
Because Claim 1 uses H/D choices in multiple positions and defines deuterated methylene variants (CD2/CHD/CH2), the most common prior-art collision is:
- earlier publications or patents disclosing the same isoindoline scaffold with deuteration at one or more positions
- later improvements that add deuteration at additional positions or vary the adjacent substituent around the scaffold
The claim style here is classic for “deuterium-enabled PK/PD improvement” series patents. That tends to lead to dense prior art around:
- the scaffold
- synthesis routes producing the deuterated intermediates
- polymorph handling and salt formation
2) Isoindoline scaffold “neighbor space”
The general formula approach can create proximity risks with:
- compounds where the same scaffold is substituted with similar alkyl/alkoxy patterns
- compounds where the heterocycle is swapped among N- or O-containing 5- and 6-membered heterocycles (pyrrolidine, morpholine, piperazine show up explicitly)
Even if competitors use a different exact substituent, claim coverage may still be triggered if the design falls inside R2’, R3’, R4’, R5’ and the allowed groups under the defined R10 substituent pattern.
3) Use claims tied to TNF-alpha
Method claims (Claims 21–23) cover diseases “caused by TNF-alpha or associated with abnormal regulation of TNF-alpha activity,” including a long list of cancers and immuno-inflammatory disorders.
Landscape collision risk usually comes from:
- older TNF-alpha antagonists or anti-TNF therapies with broad indications
- earlier patents that claim TNF-alpha therapeutic use for isoindoline derivatives or close structural analogs
If the compound is already known, the novelty question becomes:
- whether the isoindoline derivative itself is new (or at least non-obvious)
- whether deuterated variants have patentable improvements (often challenged with obviousness-type rationales)
Process claims (9–18): what they actually protect
The process claims are structured around named intermediate series:
- Claim 9: deprotection of compound A-06(1) to A-06(a1) then amidation to formula (I)
- Claim 10: reduction reaction when n1 is 0
- Claim 11: reductive amination reaction when n1 is 1 and X is NH or HD
- Claims 12–14: adding further reductions/amidations/reductive amination/nucleophilic substitution steps
- Claim 15–16: coupling reactions and deprotection/amidation sequence routes
- Claim 17: further reduction from I-RS to P-01
- Claim 18: intermediate compounds A-06(1) or A-06(a1) with defined substituent patterns and deuterium variants
From an infringement posture:
- product-by-process is not explicitly asserted in the excerpt, but process claims can still be valuable to challenge competitors’ manufacturing if they literally perform the claimed steps with the claimed intermediates.
- intermediate claims (Claim 18) can also matter if competitors sell or use those intermediates.
From an enforceability posture:
- process claims often face both scope ambiguity (where the “compound A-05(1)” labels must be mapped exactly to competitor routes) and proof burdens (actual steps, not just end product).
Claims on composition and treatment: where enforcement is easiest
Composition
Claim 19: a pharmaceutical composition comprising a therapeutically/prophylactically effective amount of the Claim 1 isoindoline family.
Claim 20 lists potential additional agents, including checkpoint inhibitors and chemotherapies (e.g., nivolumab, pembrolizumab, palbociclib, panobinostat, etc.).
The combination clause typically strengthens formulation freedom, but it does not narrow the primary active ingredient.
Method of treatment
Claim 21: administer the Claim 1 isoindoline family for diseases caused by abnormal TNF-alpha activity.
Claim 22 lists extensive diseases including numerous cancers (multiple myeloma, mantle cell lymphoma, non-Hodgkin’s lymphoma, many solid tumors) and other conditions such as amyloidosis and chronic complex regional pain syndrome.
Claim 23 covers the pharmaceutical composition of Claim 19 for the same TNF-alpha-driven indication concept.
From a landscape perspective:
- once the active ingredient is asserted inside Claim 1’s structural box, the method claims can be asserted without requiring that the clinical indication be novel.
- the main contest becomes whether the compound is new and non-obvious, not whether TNF-alpha is a known therapeutic target.
Critical assessment of claim strength and likely challenge points
1) Claim 1 breadth is high; that cuts both ways
- Strength: A competitor must either step fully outside the “general formula (I)” constraints or change the structure enough to avoid literal coverage.
- Risk: Broad deuteration-inclusive general-formula claims are frequently attacked for enablement or lack of commensurate written description across all permutations if the specification does not support each variant with adequate examples or guidance.
In this excerpt, Claim 8’s large enumerated set supports at least some breadth, but the true vulnerability turns on the written description and working examples count across the full combinatorial space.
2) Stereochemistry and polymorph are included without functional limitations
Including:
- stereoisomers (Claim 2)
- polymorphs, salts (Claim 1)
Typically strengthens enforcement because competitors cannot avoid coverage by switching salt form or isolating another polymorph, assuming the structural identity matches.
Challenge risk:
- if the specification does not clearly tie specific polymorphs/salts to the claimed isoindoline structures and their preparation/characterization, an invalidity attack can be raised.
3) R10 and R2’–R5’ define “hot spots”
Several dependent claims hinge on R10 substituent motifs and then constrain R2’–R5’. These are common “hot spots” where competitors try to design around by changing:
- whether R2’–R5’ are halogens vs alkyl vs alkoxy
- the alkyl/alkoxy chain length and branching
Because the dependent claims include narrow ranges (C1–C4 alkoxy and alkyl; F/Cl/Br/I; heterocycles restricted to pyrrolidine/morpholine/piperazine in Claim 4), competitor avoidance may be feasible by staying just outside those dependent constraints while still possibly staying outside independent claim coverage depending on what R10 exactly is in the competitor’s molecule.
4) Process claims likely face mapping and proof friction
To enforce process claims, a plaintiff must show the competitor performs the same sequence with the same intermediates and conditions as the claims require. Without access to specific reaction conditions and intermediate definitions as drawn in the full patent document, enforcement success will often depend on whether the competitor’s route can be proven step-by-step.
Practical patent landscape takeaways for strategy
Even without bibliographic data in your excerpt, the claim architecture yields actionable landscape implications:
-
Assume the competitive set includes deuterated “within scaffold” variants
- Any program working on isoindoline TNF-alpha compounds should be reviewed for deuteration substitution patterns matching Claim 1’s H/D and CD2/CHD/CH2 handling.
-
Treat the R10 substituent and R2’–R5’ as the first design-around lever
- If a competitor changes R10’s structural role and the substitution type on that motif, the Claim 1 literal path may fail, and the dependent claim constraints become irrelevant.
-
Check for pyrrolidine/morpholine/piperazine heterocycles
- Claim 4 explicitly calls out these. Competitors outside that set may still be captured by Claim 1 depending on Z and the allowed heterocycloalkyl definition in the general formula, but Claim 4 shows the likely core intended embodiments.
-
Treat “salt/polymorph/isotopic forms” as baseline coverage
- Switching to a different salt or polymorph alone usually does not defeat coverage when the claim explicitly includes them.
Key Takeaways
- US 10,017,492 is a general-formula isoindoline family patent with coverage extended across salts, polymorphs, stereoisomers, deuterated isotopic compounds, and metabolites.
- Claim 1 is the dominant claim: it defines a large combinatorial space via n1 (0/1), Z variants, X (NH/ND/O), multiple H/D positions, CD2/CHD/CH2 moieties, and an R10-dependent substitution framework for R2’–R5’.
- Dependent claims (2–8) tighten chemistry around stereochemistry, Z alternatives, heterocycle preferences (Claim 4), and R10-related substituent types (Claims 5–6), creating both enforceable specificity and exploitable design-around boundaries.
- The patent includes process claims using multi-step syntheses through named intermediates, plus intermediate compound claims, but these typically face higher proof burden than composition claims.
- Composition and TNF-alpha method-of-use claims are broad by disease list and mechanism framing, so enforceability often turns on whether a competitor’s active ingredient falls inside Claim 1’s structural box.
FAQs
-
Does the patent cover deuterated forms broadly?
Yes. Claim 1 repeatedly defines positions as independently H or D and includes CD2/CHD/CH2 variants, plus deuteration in the R10-dependent framework.
-
Is stereochemistry required to be specific for infringement?
No. Claim 2 expressly includes (S), (R), enriched (S)/(R), racemate, and achiral carbon definitions for the asymmetric center, reducing stereochemical escape routes.
-
What is the most likely design-around lever?
The R10 substituent motif and the allowed R2’–R5’ substituents (halogen vs alkyl vs alkoxy, and their chain lengths) are the clearest structural “hot spots.”
-
Can switching to a different salt or polymorph avoid infringement?
Not by itself. Claim 1 includes pharmaceutically acceptable salts and polymorphs as covered variants.
-
Are process claims easier to enforce than composition claims?
Usually composition claims are easier because they require less proof than showing exact manufacturing steps with named intermediates as in Claims 9–18.
References
- US Patent 10,017,492 (claims as provided in user excerpt).
